ATE494910T1 - Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort - Google Patents

Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort

Info

Publication number: ATE494910T1
Authority: AT; Austria
Prior art keywords: particles; boosting; composition; immune response; virus
Prior art date: 2003-07-10

Application number

AT04763176T

Other languages

English (en)

Inventor

Martin Bachmann

Katrin Schwarz

Original Assignee

Cytos Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-10

Filing date

2004-07-12

Publication date

2011-01-15

2004-07-12 Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE494910T1 publication Critical patent/ATE494910T1/de

Links

230000028993 immune response Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
239000002245 particle Substances 0.000 title abstract 2
102000002689 Toll-like receptor Human genes 0.000 abstract 2
108020000411 Toll-like receptor Proteins 0.000 abstract 2
208000017667 Chronic Disease Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
230000005867 T cell response Effects 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
230000005875 antibody response Effects 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT04763176T 2003-07-10 2004-07-12 Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort ATE494910T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48571703P	2003-07-10	2003-07-10
PCT/EP2004/007679 WO2005004907A1 (en)	2003-07-10	2004-07-12	Packaged virus-like particles

Publications (1)

Publication Number	Publication Date
ATE494910T1 true ATE494910T1 (de)	2011-01-15

Family

ID=34062090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04763176T ATE494910T1 (de)	2003-07-10	2004-07-12	Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort

Country Status (11)

Country	Link
US (1)	US20060251623A1 (de)
EP (1)	EP1644034B1 (de)
JP (1)	JP2009513532A (de)
KR (1)	KR20060031607A (de)
CN (1)	CN100404070C (de)
AT (1)	ATE494910T1 (de)
AU (1)	AU2004255470B2 (de)
CA (1)	CA2527102A1 (de)
DE (1)	DE602004031017D1 (de)
RU (1)	RU2375076C2 (de)
WO (1)	WO2005004907A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
EP1450856B1 (de)	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2503693A1 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
RU2351362C2 (ru) *	2003-03-26	2009-04-10	Цитос Байотекнолоджи Аг	КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
ES2217967B1 (es) *	2003-03-31	2006-01-01	Consejo Sup. Investig. Cientificas	Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
US9090673B2 (en) *	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2307346B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
CN101052411B (zh)	2004-10-05	2011-04-06	赛托斯生物技术公司	Vlp-抗原偶联物及其作为疫苗的用途
PL1868642T3 (pl) *	2005-03-18	2013-10-31	Cytos Biotechnology Ag	Białka fuzyjne alergenów kocich i ich zastosowania
CN101287489A (zh) *	2005-06-01	2008-10-15	陶氏环球技术公司	多价病毒样颗粒的生产
ES2310062B1 (es) *	2005-07-15	2009-11-13	Bionostra, S.L.	Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
WO2007068747A1 (en) *	2005-12-14	2007-06-21	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
AU2013204383B2 (en) *	2006-06-12	2016-09-22	Kuros Us Llc	Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
JP5437797B2 (ja)	2006-06-12	2014-03-12	サイトスバイオテクノロジーアーゲー	Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
JP4957886B2 (ja) *	2006-06-30	2012-06-20	東レ株式会社	免疫活性化能を有するカラム
EP2125854B1 (de)	2006-12-12	2016-10-26	Kuros Biosciences AG	Oligonukleotide mit hohen konzentrationen an guaninmonomeren
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2010024284A1 (ja) *	2008-09-01	2010-03-04	国立大学法人北海道大学	魚類抗ウイルスワクチン、魚類免疫賦活剤、および魚類免疫付与方法
WO2010042751A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042749A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
JP5746038B2 (ja) *	2008-11-04	2015-07-08	インデックス・ファーマシューティカルズ・アクチエボラーグ	Ｃｎｓの炎症性疾患の治療のための化合物および方法
AU2010243490A1 (en) *	2009-04-30	2011-11-24	Cytos Biotechnology Ag	Influenza hemagglutinin compositions and uses thereof
DE102009034779A1 (de)	2009-07-25	2011-02-03	Emc Microcollections Gmbh	Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
MX2013013228A (es)	2011-05-13	2013-12-12	Folia Biotech Inc	Particulas similares a virus y proceso para prepararlas.
US9683020B2 (en) *	2011-08-01	2017-06-20	Emory University	VLPS containing ligands and methods related thereto
EP3275464A1 (de) *	2011-08-01	2018-01-31	Emory University	Liganden-haltige vlps und entsprechende verfahren
GB201113570D0 (en) *	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
CN104011080B (zh)	2011-12-22	2017-10-20	弗·哈夫曼-拉罗切有限公司	用于真核细胞的全长抗体展示系统及其用途
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CN103421117B (zh) *	2012-05-16	2016-08-03	李岱宗	一种免疫增强型病毒样颗粒、其表达载体及其制备与应用
WO2014138824A1 (en) *	2013-03-15	2014-09-18	Sementis Limited	Immune modulation
EP2982681B8 (de)	2013-03-29	2018-11-07	Sumitomo Dainippon Pharma Co., Ltd.	Wt1-antigen-peptid-konjugat-vakzin
KR20160042917A (ko)	2013-07-25	2016-04-20	엑시큐어, 인크.	예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
CA2915728A1 (en)	2013-08-21	2015-02-26	Thomas Kramps	Respiratory syncytial virus (rsv) vaccine
CA2936286A1 (en)	2014-04-01	2015-10-08	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3139954A4 (de) *	2014-05-09	2018-02-28	Indiana University Research and Technology Corporation	Verfahren und zusammensetzungen zur behandlung von hepatitis-b-vireninfektionen
EP3164113B1 (de)	2014-06-04	2019-03-27	Exicure, Inc.	Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
MA40824A (fr)	2014-10-22	2017-08-29	Saiba Gmbh	Particules de cmv de type virus modifié
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10526376B2 (en)	2015-01-15	2020-01-07	University Of Copenhagen	Virus-like particle with efficient epitope display
US20180140691A1 (en) *	2015-05-20	2018-05-24	Sumitomo Dainippon Pharma Co., Ltd.	Combination use of wt1 antigen peptide and immunomodulator
EP3368068B1 (de)	2015-10-30	2020-11-18	University of Copenhagen	Virusähnliche partikel mit effizienter epitopanzeige
US20190046638A1 (en) *	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2017186808A1 (en) *	2016-04-27	2017-11-02	Allergy Therapeutics (Uk) Limited	Treatment of peanut allergy
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
US12383608B2 (en)	2016-11-30	2025-08-12	Sumitomo Pharma Co., Ltd.	WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
EP3752194A4 (de)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	Zusammensetzungen und verfahren für die tumorimmuntherapie
SG11202009647VA (en)	2018-04-09	2020-10-29	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
WO2020121062A1 (en) *	2018-12-12	2020-06-18	Anergis S.A.	Methods of improving efficacy of allergy vaccines
CN111166727A (zh) *	2019-11-15	2020-05-19	河南省生物工程技术研究中心	一种肿瘤免疫治疗复合物及其制备方法和用途
CU20200028A7 (es) *	2020-04-20	2021-11-04	Ct Ingenieria Genetica Biotecnologia	Nucleoproteína viral y formulaciones que la contienen
US20220288181A1 (en) *	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
GB202204803D0 (en) *	2022-04-01	2022-05-18	Univ Manchester	Virus-like particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ES2284161T3 (es) *	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999058118A2 (en) *	1998-05-14	1999-11-18	Cpg Immunopharmaceuticals Gmbh	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
IL148843A0 (en)	1999-09-25	2002-09-12	Univ Iowa Res Found	Immunostimulatory nucleic acids
US7320793B2 (en) *	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
EP1437013B1 (de) *	2001-09-13	2008-07-23	Airsage, Inc.	System und verfahren zur bereitstelung von verkehrsinformationen unter verwendung von betriebsdaten eines drahtlosen netzwerks
CA2492823A1 (en) *	2001-09-14	2003-03-27	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (de)	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
BR0311995A (pt) *	2002-06-20	2005-04-05	Cytos Biotechnology Ag	Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso

2004
- 2004-07-12 EP EP04763176A patent/EP1644034B1/de not_active Expired - Lifetime
- 2004-07-12 AU AU2004255470A patent/AU2004255470B2/en not_active Ceased
- 2004-07-12 WO PCT/EP2004/007679 patent/WO2005004907A1/en not_active Ceased
- 2004-07-12 CN CNB2004800159525A patent/CN100404070C/zh not_active Expired - Fee Related
- 2004-07-12 DE DE200460031017 patent/DE602004031017D1/de not_active Expired - Lifetime
- 2004-07-12 CA CA 2527102 patent/CA2527102A1/en not_active Abandoned
- 2004-07-12 JP JP2006518174A patent/JP2009513532A/ja active Pending
- 2004-07-12 AT AT04763176T patent/ATE494910T1/de not_active IP Right Cessation
- 2004-07-12 KR KR1020057022783A patent/KR20060031607A/ko not_active Ceased
- 2004-07-12 US US10/563,944 patent/US20060251623A1/en not_active Abandoned
- 2004-07-12 RU RU2006103853A patent/RU2375076C2/ru not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2009513532A (ja)	2009-04-02
US20060251623A1 (en)	2006-11-09
CN100404070C (zh)	2008-07-23
RU2006103853A (ru)	2007-08-20
DE602004031017D1 (de)	2011-02-24
WO2005004907A1 (en)	2005-01-20
AU2004255470B2 (en)	2010-08-19
KR20060031607A (ko)	2006-04-12
EP1644034B1 (de)	2011-01-12
EP1644034A1 (de)	2006-04-12
AU2004255470A1 (en)	2005-01-20
CA2527102A1 (en)	2005-01-20
CN1802173A (zh)	2006-07-12
RU2375076C2 (ru)	2009-12-10

Legal Events

Date	Code	Title	Description
2011-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004031017D1 (de)	2011-02-24	Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
Yang et al.	2022	Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Mbow et al.	2010	New adjuvants for human vaccines
ATE489969T1 (de)	2010-12-15	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
Cao et al.	2018	Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant
He et al.	2015	Advances in aluminum hydroxide-based adjuvant research and its mechanism
Campbell	2016	Development of the CpG adjuvant 1018: a case study
DE60234375D1 (de)	2009-12-24	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
Kedl et al.	2003	Epitope dominance, competition and T cell affinity maturation
Mount et al.	2013	Combination of adjuvants: the future of vaccine design
WO2004084939A8 (en)	2005-06-09	Hiv-peptide-carrier-conjugates
ATE331530T1 (de)	2006-07-15	Proteasom-influenzavirus-impfstoffzusammensetzu g
WO2005089164A3 (en)	2005-12-01	Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
ATE315405T1 (de)	2006-02-15	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
WO2008039267A3 (en)	2008-12-31	Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2004026265A3 (en)	2005-01-20	Compositions and methods for treatment of herpesvirus infections
CN116064548B (zh)	2023-07-28	一种新型CpG疫苗佐剂及其应用
ATE412428T1 (de)	2008-11-15	Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
NO20012135L (no)	2001-06-25	Forsterkede vaksiner
CN110004150B (zh)	2023-03-10	一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
ATE450545T1 (de)	2009-12-15	Impfstoff mit lawsonia intracellularis- untereinheit
PL1649287T3 (pl)	2009-04-30	Ocena szczepionek zawierających adjuwanty
WO2007005627A8 (en)	2008-10-16	Tuberculosis antigen detection assays and vaccines
ATE404152T1 (de)	2008-08-15	Pathogene impstoffe und verfahren zur deren verwendung
CN104056266B (zh)	2016-06-29	新喋呤佐剂及含新喋呤佐剂的疫苗